NovaBay Pharmaceuticals, Inc. (NBY) Earnings History
Profitable20 years of earnings data (2005–2024) · Positive TTM net income
Loading earnings history...
NovaBay Pharmaceuticals, Inc. (NBY) Earnings Overview
As of July 8, 2026, NovaBay Pharmaceuticals, Inc. (NBY) reported trailing twelve-month net income of $3M, reflecting +98.2% year-over-year growth. The company earned $0.55 per diluted share over the past four quarters, with a net profit margin of -73.8%.
Looking at the long-term picture, NBY's historical earnings data spans multiple years. The company achieved its highest annual net income of $3M in fiscal 2009.
NovaBay Pharmaceuticals, Inc. maintains positive profitability with a gross margin of 66.3%, operating margin of -59.7%, and net margin of -73.8%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including AYTU (-$34M net income, -20.4% margin), PRPH (-$24M net income, -339.3% margin), OGEN (-$10M net income), NBY has room to improve margins relative to the peer group. Compare NBY vs AYTU →
NBY Earnings vs Peers
Earnings metrics vs comparable public companies
NBY Historical Earnings Data (2005–2024)
20 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$7M | +25.1% | -$6M | $-2.53 | -73.8% | -59.7% |
| 2023 | -$10M | +9.1% | -$4M | $-138.65 | -92.2% | -39.2% |
| 2022 | -$11M | -82.1% | -$14M | $-353.59 | -73.6% | -100.1% |
| 2021 | -$6M | +47.2% | -$9M | $-184.09 | -57.1% | -86.8% |
| 2020 | -$11M | -14.3% | -$6M | $-385.53 | -111.1% | -64.7% |
| 2019 | -$10M | -47.6% | -$9M | $-593.63 | -146.4% | -142.4% |
| 2018 | -$7M | +11.6% | -$8M | $-564.17 | -52.3% | -62.9% |
| 2017 | -$7M | +43.7% | -$7M | $-591.81 | -40.6% | -40.1% |
| 2016 | -$13M | +30.7% | -$11M | $-1047.97 | -110.5% | -92.3% |
| 2015 | -$19M | -24.9% | -$21M | $-694.63 | -433.1% | -479.7% |
| 2014 | -$15M | +5.3% | -$17M | $-556.27 | -1441.6% | -1601.3% |
| 2013 | -$16M | -128.3% | -$15M | $-587.32 | -461.4% | -445.4% |
| 2012 | -$7M | -38.2% | -$8M | $-210.00 | -101.2% | -119.6% |
| 2011 | -$5M | -18.0% | -$4M | $-172.64 | -46.1% | -39.2% |
| 2010 | -$4M | -259.7% | -$5M | $-161.60 | -44.2% | -46.3% |
| 2009 | $3M | +133.2% | $3M | $105.00 | 17.2% | 17.5% |
| 2008 | -$8M | -50.3% | -$9M | $-333.14 | -120.7% | -126.6% |
| 2007 | -$5M | -2.2% | -$6M | $-526.52 | -91.3% | -99.4% |
| 2006 | -$5M | -52.6% | -$6M | $-809.37 | -344.8% | -360.5% |
| 2005 | -$3M | - | -$4M | $-624.53 | - | - |
Download Data
Export NBY earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
21+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NBY — Frequently Asked Questions
Quick answers to the most common questions about buying NBY stock.
What is NBY earnings per share (EPS)?
NBY trailing twelve-month (TTM) diluted EPS is $0.55, reflecting +98.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2005 to 2024 is available in the table on this page.
What is NovaBay Pharmaceuticals, Inc.'s net income?
NovaBay Pharmaceuticals, Inc. (NBY) trailing twelve-month net income is $3M as of 2024. Earnings grew +98.2% year-over-year.
Is NBY profitable?
Yes, NBY is profitable with a TTM net income of $3M and a net profit margin of -73.8%.
What is NBY's earnings growth rate?
NBY compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2005 to 2024.
What are NBY's profit margins?
NovaBay Pharmaceuticals, Inc. net profit margin is -73.8%, operating margin is -59.7%, and gross margin is +66.3%. Below-average margins reflect competitive or cost pressures. Return on Equity is -453.6%.
Is NBY growing earnings?
Yes, NBY earnings are accelerating — EPS growth of +98.2% exceeds the 5-year CAGR of N/A. TTM net income reached $3M. Earnings momentum is strengthening.
What was NBY's best earnings year?
NovaBay Pharmaceuticals, Inc.'s highest annual net income on record is $3M, achieved in fiscal year 2009. Earnings history on this page spans 2005 to 2024 and includes all annual and quarterly figures.
What were NBY's earnings last quarter?
NBY's most recent reported quarter was Q3 2025. Net income was $-1M with diluted EPS of $-0.22. For a full breakdown of all quarters, see the quarterly earnings table on this page.